公开(公告)号：US20230051701A1

公开(公告)日：2023-02-16

申请号：US17737403

申请日：2022-05-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Nils Lonberg ,  Alan J. Korman ,  Bryan C. Barnhart ,  Aaron P. Yamniuk ,  Mohan Srinivasan ,  Karla A. Henning ,  Ming Lei ,  Emanuela Sega ,  Angela Goodenough ,  Maria N. Jure-Kunkel ,  Guodong Chen ,  John S. Sack ,  Richard Huang ,  Martin J. Corbett ,  Joseph E. Myers, JR. ,  Liang Schweizer ,  Sandra V. Hatcher ,  Haichun Huang ,  Pingping Zhang

IPC: C07K16/40 ,  C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  G01N33/573 ,  A61K47/68 ,  A61K45/06 ,  G01N33/574

Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

公开(公告)号：US10100129B2

公开(公告)日：2018-10-16

申请号：US15520638

申请日：2015-11-19

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Nils Lonberg ,  Alan J. Korman ,  Bryan C. Barnhart ,  Aaron P. Yamniuk ,  Mohan Srinivasan ,  Karla A. Henning ,  Ming Lei ,  Emanuela Sega ,  Angela Goodenough ,  Maria Jure-Kunkel ,  Guodong Chen ,  John S. Sack ,  Richard Y. Huang ,  Martin J. Corbett ,  Joseph E. Myers, Jr. ,  Liang Schweizer ,  Sandra V. Hatcher ,  Haichun Huang ,  Pingping Zhang

IPC: A61K39/00 ,  C07K16/40 ,  C07K16/28 ,  A61K47/68 ,  C07K16/30 ,  A61K39/395 ,  A61K45/06 ,  G01N33/574

Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.

公开(公告)号：US20190062456A1

公开(公告)日：2019-02-28

申请号：US16117183

申请日：2018-08-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Nils Lonberg ,  Alan J. Korman ,  Bryan C. Barnhart ,  Aaron P. Yamniuk ,  Mohan Srinivasan ,  Karla A. Henning ,  Ming Lei ,  Emanuela Sega ,  Angela Goodenough ,  Maria Jure-Kunkel ,  Guodong Chen ,  John S. Sack ,  Richard Y. Huang ,  Martin J. Corbett ,  Joseph E. Myers, JR. ,  Liang Schweizer ,  Sandra V. Hatcher ,  Haichun Huang ,  Pingping Zhang

IPC: C07K16/40 ,  G01N33/573 ,  A61K45/06 ,  C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  A61K39/00

Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

公开(公告)号：US11352440B2

公开(公告)日：2022-06-07

申请号：US16117183

申请日：2018-08-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Nils Lonberg ,  Alan J. Korman ,  Bryan C. Barnhart ,  Aaron P. Yamniuk ,  Mohan Srinivasan ,  Karla A. Henning ,  Ming Lei ,  Emanuela Sega ,  Angela Goodenough ,  Maria N. Jure-Kunkel ,  Guodong Chen ,  John S. Sack ,  Richard Y. Huang ,  Martin J. Corbett ,  Joseph E. Myers, Jr. ,  Liang Schweizer ,  Sandra V. Hatcher ,  Haichun Huang ,  Pingping Zhang

IPC: A61K39/395 ,  C07K16/40 ,  C07K16/28 ,  C07K16/30 ,  G01N33/573 ,  A61K47/68 ,  A61K45/06 ,  G01N33/574 ,  A61K39/00

Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

公开(公告)号：US10167343B2

公开(公告)日：2019-01-01

申请号：US15432180

申请日：2017-02-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Nils Lonberg ,  Alan J. Korman ,  Bryan C. Barnhart ,  Aaron P. Yamniuk ,  Mohan Srinivasan ,  Karla A. Henning ,  Ming Lei ,  Emanuela Sega ,  Angela Goodenough ,  Maria N. Jure-Kunkel ,  Guodong Chen ,  John S. Sack ,  Richard Y. Huang ,  Martin J. Corbett ,  Joseph E. Myers, Jr. ,  Liang Schweizer ,  Sandra V. Hatcher ,  Haichun Huang ,  Pingping Zhang

IPC: C07K16/30 ,  C07K16/40 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  G01N33/573 ,  C07K16/28

Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

公开(公告)号：US09605080B2

公开(公告)日：2017-03-28

申请号：US14994828

申请日：2016-01-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Nils Lonberg ,  Alan J. Korman ,  Bryan C. Barnhart ,  Aaron P. Yamniuk ,  Mohan Srinivasan ,  Karla A. Henning ,  Ming Lei ,  Emanuela Sega ,  Angela Goodenough ,  Maria N. Jure-Kunkel ,  Guodong Chen ,  John S. Sack ,  Richard Huang ,  Martin J. Corbett ,  Joseph E. Myers, Jr. ,  Liang Schweizer ,  Sandra V. Hatcher ,  Haichun Huang ,  Pingping Zhang

IPC: C07K16/30 ,  C07K16/40 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  G01N33/573

CPC classification number: C07K16/40 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3061 ,  C07K16/3069 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/573 ,  G01N2333/916

Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.